Drug Type Bispecific antibody |
Synonyms IMC-002, IMM 0306 |
Target |
Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD47 inhibitors(Cluster of differentiation 47 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diffuse Large B-Cell Lymphoma | Phase 2 | CN | 07 Jun 2023 | |
Follicular Lymphoma | Phase 2 | CN | 07 Jun 2023 | |
Mantle-Cell Lymphoma | Phase 2 | CN | 07 Jun 2023 | |
B-Cell Lymphoma | Phase 2 | - | 01 May 2023 | |
CD20 Positive B-Cell Non-Hodgkin Lymphoma | Phase 2 | CN | 02 Mar 2020 | |
Neuromyelitis Optica | IND Approval | CN | 20 Jun 2024 | |
Systemic Lupus Erythematosus | IND Approval | CN | 19 Jun 2024 |
Phase 1 | CD20 Positive B-Cell Non-Hodgkin Lymphoma CD20-positive | 8 | ibyfcangaz(yfieumqthw) = One pt experienced treatment related serious adverse event qbwekgqoby (myiwrvrnqt ) | Positive | 24 May 2024 | ||
Phase 1 | 48 | tsavmafttk(exeplbdcty) = mjsiabxcpt yvmqcldkxt (dwstmwkyor ) View more | Positive | 24 May 2024 | |||
tsavmafttk(exeplbdcty) = ifkaqqjyul yvmqcldkxt (dwstmwkyor ) View more | |||||||
NCT05805943 (AACR2024) Manual | Phase 1 | 48 | zageyvgmcu(jwgwksdugt) = The most frequent treatment related adverse events (TRAEs) were WBC decreased (66.7%), anemia (64.6%), lymphocyte decreased (58.3%), ANC decreased (47.9%), PLT decreased (45.8%), infusion-related reactions (35.4%) cbsqivdvqd (vqedypufhc ) View more | Positive | 05 Apr 2024 | ||
CTR20192612 (ASCO2023) Manual | Phase 1/2 | CD20 Positive B-Cell Non-Hodgkin Lymphoma CD20 Expression | 42 | xieuobvrpa(omfybysrcb) = Three treatment related SAEs were PLT decreased (grade 4), chest pain (grade 2) and diarrhea (grade 3). bteojobwvo (gkckvqzozt ) View more | Positive | 31 May 2023 |